If your clinician recommends testosterone, the label on the gel may give you pause: the product was made for men.

For an American woman seeking help with distressing low sexual desire after menopause, that can be part of a legitimate treatment plan. There is still no FDA-approved testosterone product specifically for women. A prescriber may instead use a much smaller dose of an approved male product, a practice called off-label prescribing.

That leaves you with questions a prescription alone cannot answer. What should improve? How will the dose be checked? And how much do we know about taking it for years?

In this article

More women are asking. The evidence still has limits.

A Truveta analysis reported by Reuters found that the rate of women receiving testosterone prescriptions rose 146% between January 2023 and July 2026. That measures prescribing, not whether treatment worked.

On September 17, the FDA held a workshop on testosterone use in menopausal women. Its stated aim was to examine the evidence and gaps that could guide future research and drug development. The workshop itself was not a product approval.

The questions include long-term heart and breast safety, how to interpret testosterone levels, and which symptoms treatment can reliably improve. A product designed for women could make prescribing more straightforward. It would not, by itself, settle those questions.

Sources: 1, 2, 7

The clearest evidence is for one specific problem

The strongest evidence is for women past menopause whose ongoing loss of sexual desire causes distress. Clinicians call this hypoactive sexual desire disorder, or HSDD. Assessment should include other possible contributors before treatment is considered.

In trials, testosterone improved desire and sexual satisfaction and reduced distress. Women had about one additional satisfying sexual experience a month, on average, compared with placebo. Some benefited more, some less, and some did not benefit.

Some specialist guidance also discusses treatment for women nearing menopause, but the evidence in that group is more limited. Low desire that does not bother you is not automatically a disorder.

Sources: 4, 5

A blood-test number cannot make the decision

There is no single testosterone result that diagnoses HSDD. A blood test can help a prescriber assess and monitor treatment; it cannot establish why your desire has changed.

The Endocrine Society’s guidance also cautions against diagnosing a general testosterone-deficiency syndrome in otherwise healthy women. Measuring the small amounts of testosterone in women accurately can be difficult, and a low result alone does not show that treatment will help.

Pain with sex, poor sleep, depression, anxiety, medicines, other illnesses and relationship concerns can all matter. Tell your clinician what has changed and what you want help with, even if the conversation feels awkward.

The aim is meaningful improvement in a symptom that troubles you. A higher laboratory number is not, on its own, evidence of a better result.

Sources: 4, 5, 8

The promises often go beyond the research

Testosterone is also promoted for tiredness, brain fog, mood, weight loss and muscle. Research has not established it as a reliable treatment for these concerns or as a way to live longer.

Studies at doses intended for women have not shown a clear improvement in muscle strength, lean mass or bone density. Evidence is also insufficient for preventing cognitive decline. If exhaustion, forgetfulness or loss of strength is your concern, it deserves its own assessment.

An individual woman may feel better while taking testosterone. Her experience matters, but it cannot tell us which benefits other women should expect.

Sources: 4, 5

The product and the dose matter

Guidance generally favors testosterone absorbed through the skin, such as a gel or cream, when treatment is appropriate. The dose is chosen for women and checked with blood tests to avoid levels above the usual premenopausal range. An approved male product used off-label is different from a compounded preparation, which has not itself been FDA-approved.

Compounded medicines do not undergo the FDA’s premarket checks for safety, effectiveness and quality. Sexual-health guidance advises against compounded testosterone. A description such as natural or personalized does not establish safety.

Testosterone taken by mouth can worsen cholesterol and is generally not recommended for women. Short-term studies of treatment through the skin have not shown the same adverse cholesterol effects at doses intended for women. High-dose injections or pellets that raise testosterone above the usual female range are not recommended. Pellets also make prompt dose adjustment difficult.

Ask your prescriber and pharmacist to explain the exact amount and how to measure it. Do not estimate a fraction of a male dose yourself. Ask how to avoid transferring a topical product to someone else through skin contact.

Sources: 4, 5, 6

Short-term reassurance has an important boundary

Short trials of testosterone at doses intended for women did not show a clear increase in serious adverse events. The participants and the length of those trials matter: women at high cardiovascular risk were generally excluded, and many participants were also taking estrogen.

The international consensus review did not have randomized-trial safety data beyond 24 months. That leaves uncertainty about heart attacks, death and breast cancer over years of treatment. Short-term findings cannot simply be extended to women at higher risk.

Testosterone has not been shown to prevent heart disease. Bring your blood pressure, cholesterol, blood sugar, pregnancy and family history, medicines and breast health history into the decision.

Sources: 1, 4, 5

Follow-up should be part of the prescription

Before starting, agree on the symptom you want to improve and when you will review it. Blood testing helps prevent excessive dosing; it does not replace asking whether you feel better.

  • Before treatment: Review your health history and medicines. Guidance recommends total testosterone, SHBG (a protein that carries hormones), cholesterol and liver blood tests.
  • Early checks: Recheck testosterone 3–6 weeks after starting and again 3–6 weeks after a dose adjustment. Your prescriber may check sooner if a level is too high.
  • Once stable: Recheck about every 4–6 months and review symptoms and side effects.
  • Side effects: Report acne, extra facial or body hair, scalp hair thinning or voice changes. The dose or treatment may need to change.
  • By six months: If there is no meaningful benefit, guidance recommends stopping treatment and reassessing the cause of the problem.

Sources: 5

Leave with a plan you can explain

You deserve to have a distressing change in sexual desire taken seriously. Before you say yes to testosterone, ask: “What are we treating, what improvement should I expect, and when will we decide whether it is helping?”

Bring your wider health history, too. The right conversation makes room for both the symptom affecting your life now and the safety questions that still need answers.

Your next step

Define what improvement would mean

Before a treatment discussion, describe what is bothering you, how long it has lasted and medicines or life changes that may be relevant. If testosterone is prescribed, ask about the exact formulation, dose, monitoring and review date.

Before you leave, confirm the next step, when it should happen, and who will follow up.

Free. No account needed. Use your notes with your care team.

Evidence behind the article

Sources and editorial review

Updated and sources checked:

  1. Testosterone Use in Menopausal Women: Public WorkshopU.S. Food and Drug Administration · September 17, 2026 · Workshop information checked September 17
  2. Testosterone Use in Menopausal Women: Workshop NoticeU.S. Food and Drug Administration · Federal Register · August 18, 2026
  3. Accelerating Testosterone Prescribing for U.S. Women: Implications for Cardiovascular SafetyAvivi and colleagues · JACC: Advances · 2026
  4. Global Consensus Position Statement on the Use of Testosterone Therapy for WomenDavis and colleagues · International consensus · 2019
  5. Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in WomenInternational Society for the Study of Women’s Sexual Health · 2021
  6. Understanding the Risks of Compounded DrugsU.S. Food and Drug Administration · Accessed September 2026
  7. Testosterone scripts for women rise, along with denials and delaysReuters · Original reporting and Truveta analysis · September 15, 2026
  8. Androgen Therapy in Women: A ReappraisalEndocrine Society · Clinical Practice Guideline · 2014

Independent clinical review is identified only when it has been completed and approved in writing. No external reviewer or organization is implied. Sources do not imply endorsement of HEART RESERVE.